Multiple Myeloma

Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

multiple myeloma

[′məl·tə·pəl ‚mī·ə′lō·mə]
A primary bone malignancy characterized by diffuse osteoporosis, anemia, hyperglobulinemia, and other clinical features. Also known as Kahler's disease.

Multiple Myeloma


a disease of the bone marrow of the group of plasma cell dyscrasias. It is caused by proliferation of genetically altered (mutated) plasma cells of the bone marrow which synthesize and release into the blood a large quantity of proteins with various physicochemical, biochemical, and immunochemical properties. Multiple myeloma is manifested by changes in the skeletal, hematopoietic, and uropoietic systems and by disturbances in protein and mineral metabolism. Spontaneous fractures and, sometimes, tumors originating in the bone marrow are observed. The bone resorption leads to hypercalcemia, and the excess calcium is deposited in the excretory organs (kidneys, lungs, gastric mucosa) in the form of calcifications. There is renal dysfunction (myeloma kidney) resulting mainly from filtration of abnormal proteins by the kidney. Frequent bacterial infections are characteristic of multiple myeloma because of the decrease in the number of normal immunoglobulins and the disruption of antibody formation.

Treatment consists of chemotherapy, irradiation, and hormonal therapy. Infection is treated by antibiotics and gamma globulin. Proper orthopedic measures are also of great value.


Alekseev, G. A., and N. E. Andreeva. Mielomnaia bolezn’. Moscow, 1966.
Kassirskii, I. A., and G. A. Alekseev. Klinicheskaia gematologiia, 4th ed. Moscow, 1970.
Burnet, F. M. Kletochnaia immunologiia. Moscow, 1971. (Translated from English.)


References in periodicals archive ?
Majority of the studies on genetic aberrations in multiple myeloma include western population.
CA204142: A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide
It is a rare but deadly disease: around 39,000 people are diagnosed with multiple myeloma in Europe, and around 24,000 people die from the disease each year.
The researchers found that as a patient's BMI increased, fat cells communicated with multiple myeloma cells.
These findings were consistent with multiple myeloma.
UAMS treats more than 2,250 patients with multiple myeloma annually at the Myeloma Institute, more myeloma patients than are treated at any other facility in the country.
The findings of this spike and the bone marrow plasmacytosis strongly suggested a diagnosis of multiple myeloma.
Designed to be collaborative, INSIGHT-MM remains open for the multiple myeloma community to propose analyses and request data that has been collected during the study.
The USD1m trial will be funded and conducted by the Multiple Myeloma Research Foundation (MMRF), a consortium of 16 world-renowned academic institutions and community centres whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma.
Depending on their site of development and clinical features, malignant tumors of monoclonal antibody-producing plasma cells are classified as either multiple myelomas, solitary plasmacytomas, or extramedullary plasmacytomas.

Full browser ?